Cytodyn Inc at Cytodyn Inc Next Super Stock Live Hosted by Wall Street Reporter Transcript
Thank you, Jack, and thanks for everyone to be on this call. I am excited to present our company, Cytodyn, to everyone. But in today's presentation, I will be doing things a little bit different. I will take my time a little bit more and give everybody a background of how leronlimab PRO 140 had to overcome many odds that most people don't know about.
In today's presentation, obviously, I will be making a lot of forward-looking statement like always. So, leronlimab is our lead product, and it used to be called PRO 140. It is a humanized monoclonal antibody. How do we get these products? In 2011, I found out that PRO 140 at Progenics was going to be sold and they shelved the product. They were not going to develop it. They were not able to sell the product. However, we thought that we could buy it and do something with this product.
We bought it for a very low down payment of $3.5 million. Anybody will know that the product in Phase 2 worth a lot more than that. But because nobody had a vision for this product going forward due to the lengthy trials ahead
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
